Chronic traumatic encephalopathy (CTE) …

Neurobehavioral & Cognitive Disorders

Updated 04.28.2023
Released 11.01.1994
Expires For CME 04.28.2026

Chronic traumatic encephalopathy

Authors: Jason L Weller MD, Katherine Turk MD, Andrew E Budson MD

See Contributor Disclosures

Editor: Howard S Kirshner MD

Chronic traumatic encephalopathy

In This Article

Quick Link

Introduction

Overview

Traumatic encephalopathy refers to a specific pathology found in the brains of people with a history of traumatic brain injury. Although first recognized as a clinical entity in the early 20th century, it has become an increasingly controversial topic in both the scientific and sporting communities over the past few decades. This article provides a look into its history and epidemiology as well as a summary of current research into the evaluation, diagnosis, and management of this neurodegenerative disease.

Key points

	• Chronic traumatic encephalopathy is a neuropathological term describing abnormal protein deposits in a specific pattern in the brain; traumatic encephalopathy syndrome is the term used for the clinical presentation associated with disease.
	• The clinical presentation includes a progressive form of dementia similar to, but distinct from, Alzheimer disease.
	• The only known risk factor is a history of either multiple mild or at least one moderate to severe traumatic brain injury; signs and symptoms of disease often begin years or even decades after the last reported head injury.
	• To date, more than 99% of cases of symptomatic former professional American football players tested were confirmed to have chronic traumatic encephalopathy at autopsy; an all-cause dementia brain bank found no evidence of the disease in cases without documented head trauma and 32% prevalence in those with history of contact sports participation.
	• As with other neurodegenerative diseases, there is no cure for chronic traumatic encephalopathy, and treatment is largely symptomatic.
	• Current research is underway to diagnose the clinical traumatic encephalopathy syndrome, and subsequently chronic traumatic encephalopathy, in living patients using clinical evaluation criteria and biomarkers, such as serum, cerebrospinal fluid, and imaging studies.

Historical note and terminology

Chronic traumatic encephalopathy was first described in 1928 as the clinical “punch drunk syndrome.” It was associated with people who participated in the sport of boxing, particularly those athletes who received multiple blows to the head. Pathological findings attributable to chronic traumatic encephalopathy were later published, also using former professional boxers as case studies. This entity went largely unnoticed by the general public until 2005 when the first reported case was found in a former professional American football player. Since then, chronic traumatic encephalopathy has become the focus of media attention with respect to prevention and management of brain injury in sports, particularly American football. The scientific community has likewise developed a renewed interest in the study of chronic traumatic encephalopathy, and multiple studies are currently underway to better understand this disease. The neuropathology of chronic traumatic encephalopathy has been confirmed as distinct from other forms of neurodegenerative disease, and the search continues for in vivo diagnostic and therapeutic options.

Clinical manifestations

Presentation and course

At present, the only definitive risk factor for the diagnosis of chronic traumatic encephalopathy is a history of repetitive head injury. The diagnostic criteria for presenting signs and symptoms consist of mood and behavioral changes, cognitive difficulties, motor dysfunction, and dementia (34). Retrospective analysis revealed mood changes in 96% of confirmed cases of neuropathologically mild chronic traumatic encephalopathy, compared with 89% of those with severe chronic traumatic encephalopathy (32). Cognitive symptoms were present in 85% of mild cases and 95% of severe cases, whereas dementia was reported in 33% of mild and 85% of severe cases. Motor symptoms, such as tremor, dysarthria, and dyscoordination, were present in 48% of mild cases and 75% of severe cases of confirmed chronic traumatic encephalopathy. Table 1 lists the most commonly described symptoms at initial presentation for chronic traumatic encephalopathy of any stage.

Table 1. Most Common Initial Presenting Clinical Features Among Symptomatic Subjects

•·Memory impairment (84.8%)
•·Executive dysfunction (78.8%)
•·Attention and concentration difficulties (72.7%)
•·Sadness or depression (63.6%)
•·Hopelessness (63.6%)
•·Explosivity (57.6%)
•·Language impairment (57.6%)
•·Visuospatial difficulties (54.5%)
•·“Out of control” (51.5%)
•·Physically violent (51.5%)
•·Verbally violent (48.5%)
•·Impulse and control problems (45.5%)
•·Suicidal ideation or attempts (30.3%)

% Indicates the percentage of symptomatic individuals with autopsy proven CTE endorsing each feature at initial presentation.

Adapted from (47).

Time course and prognosis. Retrospective analysis revealed progressive decline comparable to other neurodegenerative disorders in 68% of confirmed chronic traumatic encephalopathy cases (34). However, the presence of chronic traumatic encephalopathy in younger patients with primarily mood and behavioral symptoms suggests a more slow-moving or even static process than the progressive cognitive symptoms noted in patients who are older at initial presentation (33; 34). Given the estimated progression between subsequent stages of chronic traumatic encephalopathy of 11 to 14 years, this discrepancy may represent at least two distinct subtypes of chronic traumatic encephalopathy, which also makes accurate diagnosis difficult in living patients and has led to the development of a classification system based on the presenting symptoms (30; 34). Barry Jordan proposed in 2013 a set of clinical criteria to associate symptomatology with the likelihood of chronic traumatic encephalopathy, creating categories of definite (pathology-proven), probable, possible, and improbable (19). These categories were further expanded to include subtypes of behavior or mood, cognitive, mixed, and dementia presentations as well as to account for future diagnostic biomarker evaluation (34). Average age of onset appears to have two distinct peaks: 34.5 years for behavioral or mood variant, and 58.5 years for the cognitive variant. Although true prevalence is unknown, retrospective analysis revealed 28% of confirmed cases presented with behavioral and mood disturbances as the major complaint, 32% presented with cognitive difficulty in the absence of mood changes, and 40% presented with both behavioral and cognitive complaints.

Despite the classification of chronic traumatic encephalopathy as a neuropathological diagnosis possible only via postmortem analysis, a survey reported a clinician’s diagnosis of chronic traumatic encephalopathy in living former football players in 108 of 3913 (2.8%) respondents (14). To delineate between the clinical presentation and neuropathological findings, the term traumatic encephalopathy syndrome was introduced to describe the clinical research criteria associated with these subtypes (34). Although the proposed traumatic encephalopathy syndrome criteria also require a history of traumatic brain injury, they allow for a diagnosis to be made in the absence of neuropathology. The five required criteria, core and supportive clinical features, and classification scheme are outlined in Table 2. These criteria were recently updated in 2021 by a group of 20 field experts who performed an extensive literature review and application of previously published criteria for chronic traumatic encephalopathy to achieve consensus on core clinical features, supportive symptoms, and level of certainty regarding underlying chronic traumatic encephalopathy pathology. The currently accepted criteria still include supportive features such as delayed onset, psychiatric symptoms, and presence or absence of parkinsonism, but these are no longer required for diagnosis. Additionally, imaging and fluid biomarkers were not included with the current criteria with the expectation that these will be incorporated as more evidence becomes available.

Table 2. Research Diagnostic Criteria for Traumatic Encephalopathy Syndrome

	(1) Substantial exposure to repetitive head impacts, including:
		(a) Involvement in high-exposure contact or collision sports
			(i) For American football, minimum 2 years (preferably 5) at the high school level or above
		(b) Military service involving repetitive head impacts
		(c) Other exposure to multiple head impacts
	(2) One or both core clinical features, including:
		(a) Cognitive impairment (all four required)
			(i) As reported by self, informant, or clinician’s report
			(ii) Representing a significant decline from baseline level of function
			(iii) Deficits in episodic memory and/or executive function
			(iv) Substantiated by impaired performance on formal neuropsychological testing (if available)
		(b) Neurobehavioral dysregulation (all three required)
			(i) As reported by self, informant, or clinician’s report
			(ii) Representing a significant change from baseline level of function
			(iii) Symptoms and/or observed behaviors representing poor regulation or control of emotions and/or behavior, including (but not limited to) explosiveness, impulsivity, rage, violent outbursts, short fuse, or emotional lability, preferably substantiated by standardized measures
	(3) Progressive course is a required core clinical feature
	(4) Not fully accounted for by other disorders
Adapted from (21)

Diagnostic evaluation with biomarkers is an area of active research, with several possible candidates in early development. Of these, neuroimaging with amyloid- and tau-specific PET scanning appears to hold the most promise for accurate diagnosis in living patients (10; 49; 36), with the expectation that the amyloid would be negative and p-tau positive in most cases. A case-control study utilizing tau- and amyloid-specific PET scans of 26 symptomatic former National Football League players and 31 healthy, age-matched controls showed elevated standard uptake value ratios of p-tau in the study group, suggesting that these scans may aid in diagnosis (46). However, standard cognitive screening tests did not show significant differences between the two groups. Furthermore, two related studies analyzing tau-PET imaging in both postmortem, pathology-proven chronic traumatic encephalopathy and living patients who matched criteria for traumatic encephalopathy syndrome failed to show significantly elevated levels of p-tau compared to controls (24; 26). Cerebrospinal fluid analysis for total tau, p-tau, and amyloid levels is useful in ruling out the diagnosis of Alzheimer disease when advanced imaging is either contraindicated or prohibited by cost and may provide supportive data for patients with suspected chronic traumatic encephalopathy (35). Additional CSF biomarkers, including neurofilament light protein and glial fibrillary acidic protein, are under investigation as are serum studies for related proteins. A study of postmortem brain tissue found increased levels of the protein CCL2 in cases of confirmed chronic traumatic encephalopathy pathology, but not in confirmed Alzheimer disease cases, suggesting a potential future therapeutic target (08). Supportive data, including structural imaging studies (MRI and CT) with evidence of cortical atrophy and septal abnormalities, have also been evaluated (34). One study found that up to 94% of retired football players had evidence of cavum septum pellucidum, versus only 18% of control patients (13). However, this finding likely represents a marker of prior head trauma that is unlikely to be related in any direct way to chronic traumatic encephalopathy pathology.

Co-occurrence of neuropathology. Chronic traumatic encephalopathy pathology can be found alongside that of other neurodegenerative diseases commonly seen in older individuals (30). The chronic traumatic encephalopathy brain bank of the Veterans Affairs-Boston University-Concussion Legacy Foundation (VA-BU-CLF) reported 142 confirmed cases of chronic traumatic encephalopathy, of which 15 also had Alzheimer disease, another 15 had motor neuron disease, 10 had Lewy body disease, and four had frontotemporal lobar degeneration (29). Seven of the cases showed evidence of at least two other comorbid pathologies, whereas just 89 of the 142 showed pure chronic traumatic encephalopathy pathology. TDP-43 is also commonly found in cases of chronic traumatic encephalopathy, though its pattern of accumulation appears to be variable (42). One theory is that TDP-43 deposition follows a staged progression similar to p-tau and spreads from the subcortical white matter through the medial temporal lobe to involve larger cortical structures in late-stage chronic traumatic encephalopathy (30). This is supported by the observed and almost universal finding of TDP-43 in cases of stage IV chronic traumatic encephalopathy (29). TDP-43 has also been implicated in both sporadic and familial forms of motor neuron disease and frontotemporal lobar degeneration, suggesting a class of neurodegenerative diseases known at TDP-43 proteinopathies (25). However, the exact relationship between chronic traumatic encephalopathy and other neurodegenerative disease pathologies is unknown. Though the likelihood of development of Alzheimer disease increases as individuals age, the abnormal beta-amyloid (Aβ) plaques associated with Alzheimer disease are felt to arise earlier in people with repetitive head injury (45). In about one third of cases of comorbid chronic traumatic encephalopathy and motor neuron disease pathology, patients were reported to present with cognitive and behavioral changes many years before onset of motor symptoms (29). Thus, chronic traumatic encephalopathy is commonly found in concert with evidence of other neurodegenerative conditions, though investigation is underway to determine whether associations exist between these diseases.

Risk factors. Understanding whether there is a genetic predisposition for chronic traumatic encephalopathy is an active area of investigation. The APOEε4 allele on chromosome 19 confers higher risk of Alzheimer disease development and has been associated with greater cognitive impairment in former boxers and American football players (33). In a cohort of 68 confirmed chronic traumatic encephalopathy cases, the carrier frequency of APOEε4 did not differ from that found in the general population, but there was a higher rate of homozygotes in cases of pure chronic traumatic encephalopathy without comorbid neurodegenerative disease (30; 47). An analysis of 264 subjects with confirmed chronic traumatic encephalopathy showed a significant association between APOEε4 status and chronic traumatic encephalopathy stage in donors older than 65, independent of Aβ status. A few nonheritable chronic traumatic encephalopathy risk factors have also been identified, including age at first exposure to repetitive head injury and cumulative exposure. A study of 214 former American football players revealed twice the risk of behavioral changes (such as executive dysfunction and apathy), and three times the risk of clinical depression in those who began playing prior to age 12 compared to those who began later in life (01). Another study found changes in white matter integrity in boys aged 8 to 13 years after a single season of tackle football (04). These findings suggest that exposure to repetitive head injury during critical periods of neural development could result in long-term detriment. Cognitive reserve, by contrast, has been observed as a protective factor. In a study of cognitive reserve in former football players with confirmed late-stage (III or IV) chronic traumatic encephalopathy, those who attained professional, technical, or managerial post-football careers manifested cognitive and behavioral symptoms later than those who served in sales, service, construction, or other occupations requiring less than a college education (02). Interestingly, level of education itself did not significantly affect age of symptom onset.

Prognosis and complications

Chronic traumatic encephalopathy is classified as a neurodegenerative disease, a group of disorders that includes Alzheimer disease, frontotemporal dementia, Parkinson disease, amyotrophic lateral sclerosis, and Lewy body disease. As such, the prognosis for all of these diseases is poor. Clinically, symptoms generally progress over years to decades depending on initial presentation. Treatments are aimed toward symptom management and do not alter the time course significantly. For patients who presented with mood or behavioral symptoms, death commonly occurred via suicide, and patients who presented with cognitive symptoms often succumbed to complications of dementia.

Clinical vignette

A former professional NFL player started to play football at 12 years of age, including 4 years in high school, 4 years of Division I college football, and 5 years of professional football. His wife described him, in his thirties, as a bigger-than-life, charismatic personality who was very confident, caring, and giving. His family history consisted of depression in his mother and Alzheimer dementia late in life in his father.

In his mid-to-late 40s, he began to have a short fuse, with his mood changing “on a dime.” He would lose his temper over small things like someone cutting him off on the road or misplacing an object at home. He had a road-rage incident wherein he was riding a bike and someone cut him off, and he became physically aggressive, leading to an altercation with the police. All of this was unusual for him.

He had daily headaches from his 30s until his death in his 60s and was regularly taking ibuprofen. His memory worsened, and he began to use sticky notes all over the house on every surface to remind him to go to an appointment or to turn the stove off. Despite these notes, he still often forgot to turn the stove off.

His speech was generally fluent, and he understood others well, but in his 50s he began to pause in conversation, searching for the appropriate word. He was still able to do the taxes and remember to take his car to get an oil change until his death. He began shopping inappropriately in the last 4 to 5 years of his life, frequently buying expensive new vehicles impulsively, without consulting his wife.

He had a minor elective foot surgery in his 50s, and then became apathetic, refusing to shower and shave. He became obsessive about the temperature of the house to keep the pipes from freezing and would also become overly protective about his wife’s safety, calling her when she was out at night multiple times asking her to come home immediately, which was unlike him as a younger man.

He expressed suicidal ideation passively in his 60s. He had no tremor or gait difficulty and remained physically active until his death. He died by self-inflicted gunshot wound to the chest at 66 years of age. Autopsy of his brain at Boston University revealed stage II chronic traumatic encephalopathy.

Biological basis

Etiology and pathogenesis

Currently, chronic traumatic encephalopathy can only be diagnosed postmortem. Corsellis first analyzed the brains of 15 deceased former professional boxers with reported dementia in 1973, describing both gross structural changes and microscopic neuropathology (11). More than 3 decades passed before the landmark discovery of similar pathology in a former professional American football player by Omalu and colleagues (38). Finally, the National Institute of Neurological Disorders and Stroke, in association with the National Institute of Biomedical Imaging and Bioengineering (NINDS-NIBIB), published reliable, consensus-based neuropathological criteria for the diagnosis of chronic traumatic encephalopathy, which includes the pathognomonic irregular, perivascular distribution of hyperphosphorylated tau (p-tau) at the depths of cerebral sulci (29).

Another supportive but not necessary finding is deposition of a 43 kilodalton TAR DNA-binding protein (TDP-43) within the medial temporal lobes, amygdala, and hippocampus. Gross abnormalities that may be present along with multifocal cortical atrophy are third ventricular dilatation, abnormalities of the septum, including fenestration or cavum septum pellucidum or cavum vergae, and cerebral contusions or other signs of traumatic brain injury.

Multiple studies have purported to identify chronic traumatic encephalopathy pathology in the brains of donors with no apparent history of traumatic brain injury (29). On further review, the pathology described in these brains was more consistent with 4R immunoreactive “thorn-shaped astrocytes” in the subpial, periventricular, and perivascular white matter, also known as age-related tau astrogliopathy (ARTAG). This pathology also commonly occurs in normal aging and other neurodegenerative diseases. Although the presence of ARTAG is considered supportive evidence, the absence of any pathognomonic lesions greatly reduces the likelihood and does not meet neuropathological criteria for chronic traumatic encephalopathy.

Table 3 provides the full criteria recommended by NINDS-NIBIB. Chronic traumatic encephalopathy is classified from stage I (early) to stage IV (late) based on the amount and distribution of p-tau (30). Through collateral information obtained postmortem, each stage may present with an array of clinical signs and symptoms (32). Based on these clinicopathological correlations, researchers developed potential clinical criteria for the diagnosis of chronic traumatic encephalopathy in living patients, though the validity of this scheme remains under investigation (34).

Table 3. Preliminary NINDS Pathologic Criteria for Chronic Traumatic Encephalopathy Diagnosis

Required for diagnosis of CTE:
	(1) The pathognomonic lesion consists of p-tau aggregates in neurons, astrocytes, and cell processes around small vessels in an irregular pattern at the depths of the cortical sulci.
Supportive neuropathological features of CTE:
p-Tau-related pathologies:
	(1) Abnormal p-tau immunoreactive pretangles and NFTs preferentially affecting superficial layers (layers II-III), in contrast to layers III and V as in AD
	(2) In the hippocampus, pretangles, NFTs or extracellular tangles preferentially affecting CA2 and pretangles and prominent proximal dendritic swellings in CA4. These regional p-tau pathologies differ from the preferential involvement of CA1 and subiculum found in AD
	(3) Abnormal p-tau immunoreactive neuronal and astrocytic aggregates in subcortical nuclei, including the mammillary bodies and other hypothalamic nuclei, amygdala, nucleus accumbens, thalamus, midbrain tegmentum, and isodendritic core (nucleus basalis of Meynert, raphe nuclei, substantia nigra and locus coeruleus)
	(4) P-Tau immunoreactive thorny astrocytes at the glial limitans most commonly found in the subpial and periventricular regions
	(5) P-Tau immunoreactive large grain-like and dot-like structures (in addition to some threadlike neurites)
Non-p-tau-related pathologies:
	(1) Macroscopic features: disproportionate dilatation of the third ventricle, septal abnormalities, mammillary body atrophy, and contusions or other signs of previous traumatic injury
	(2) TDP=43 immunoreactive neuronal cytoplasmic inclusions and dot-like structures in the hippocampus, anteromedial temporal cortex and amygdala
Age-related p-tau astrogliopathy that may be present; non-diagnostic and non-supportive:
	(1) Patches of thorn-shaped astrocytes in subcortical white matter
	(2) Subependymal, periventricular, and perivascular thorn-shaped astrocytes in the mediobasal regions
	(3) Thorn-shaped astrocytes in amygdala or hippocampus
Adapted from (29).

Epidemiology

The true incidence and prevalence of chronic traumatic encephalopathy within the general population is unknown. Among patients with a history of contact sports involvement at the professional level, the reported rate varies from 17% to 99%, depending on the series and sports studied (41; 32). Most of the reported data suffer from some degree of ascertainment or selection bias, given that symptomatic individuals were more likely to be recruited for such studies. People with a variety of sources of repetitive head injury have been found to have chronic traumatic encephalopathy at autopsy, including players of soccer, ice hockey, rugby, wrestling, and American football as well as boxers and victims of domestic violence (38; 39; 30; 40; 31; 07). Chronic traumatic encephalopathy also has been found in the brains of deceased military veterans, both with and without a history of contact sports participation (28). Bieniek and colleagues applied the 2015 NINDS-NIBIB consensus guidelines to 1,721 brains at the Mayo Clinic Brain Bank to estimate chronic traumatic encephalopathy prevalence (05). They found chronic traumatic encephalopathy in 32% of cases with history of contact sports, compared to no chronic traumatic encephalopathy in 195 cases with either no reported head trauma or a single traumatic brain injury. However, these cases were also selected from a brain bank designated for symptomatic individuals and, thus, were susceptible to selection bias as well.

The literature regarding concussion prevalence estimates between 2 and 4 million reported sports-related concussions per year in the United States alone (22). Furthermore, the rate of asymptomatic or subconcussive head trauma appears to be exponentially higher than that of symptomatic concussions (27). Through the use of accelerometers implanted into helmets, one study estimated that the average high school football player incurs 652 head strikes of more than 15G acceleration, none of which resulted in acute clinical symptoms or a diagnosis of concussion (06).

The reported prevalence of head injuries among active-duty military personnel in this century is nearly 25% (37). Posttraumatic stress disorder affects nearly 20% of Gulf War veterans (17). A 2008 study showed that nearly half of veterans returning from the war in Iraq who suffered loss of consciousness as a result of traumatic brain injury also fulfilled diagnoses of posttraumatic stress disorder, compared to only 9.1% of Iraq war veterans without traumatic brain injury (18). Unfortunately, symptoms such as irritability, memory and concentration difficulties, sleep disturbances, and headaches are common to chronic traumatic encephalopathy as well as posttraumatic stress disorder and postconcussion syndrome (43). What is unknown is whether some of these same posttraumatic stress disorder symptoms could be present or exacerbated in some patients by indolent, underlying chronic traumatic encephalopathy pathology.

Although the age of initial presentation for chronic traumatic encephalopathy is estimated to be between 30 and 65 years, chronic traumatic encephalopathy pathology has been seen in patients as young as 18 years (33). Like other neurodegenerative diseases, chronic traumatic encephalopathy is purported to begin with deposition of p-tau years or even decades before symptoms of traumatic encephalopathy syndrome arise. More inclusive prospective studies are needed to define the true epidemiology of chronic traumatic encephalopathy.

Diagnostic workup

Clinical evaluation. Patients with suspected chronic traumatic encephalopathy should be evaluated for the presence of mood and behavioral symptoms as well as difficulty with memory and cognition. Age of onset and interval progression of symptoms should be elicited as chronic traumatic encephalopathy is associated with functional decline analogous to other neurodegenerative disorders. Clinicians should inquire about history of contact sports (age of first exposure, years played, amateur or professional), military history (deployment to active combat zone), domestic violence, motor vehicle collisions, and other sources of head trauma with or without a diagnosis of concussion. A detailed neurologic examination should include a comprehensive mental status examination and motor, coordination, and gait evaluations as well as surveillance for signs of parkinsonism or motor neuron disease, both of which have been reported in patients with history of repetitive head injury (23).

Biomarkers. Investigation continues into the use of biomarkers for the diagnosis of chronic traumatic encephalopathy in living patients. Given that chronic traumatic encephalopathy is a disease of abnormal tau protein accumulation, serum evaluation for total tau (t-tau) has been investigated. One study showed elevated levels only in former professional American football players (03). However, elevated serum t-tau levels did not correlate with abnormal clinical function and were also found in brain diseases such as stroke, Alzheimer disease, and frontotemporal lobar degeneration (15).

Obtaining a lumbar puncture for analysis of CSF for markers of acute brain injury may include t-tau, glial fibrillary acid protein (GFAP), and neurofilament light protein, all of which have been found at elevated levels in Olympic boxers within 1 week post-bout (35). In some cases, neurofilament light protein and GFAP remained elevated long after normalization of other CSF proteins, possibly indicative of continuing neurodegeneration. An analysis of postmortem CSF samples obtained from participants with confirmed chronic traumatic encephalopathy showed elevated levels of p-tau231 and reduced levels of Aβ1-42 compared to controls and participants with confirmed Alzheimer disease (48).

One study found increased levels of a protein called eotaxin-1 (CCL11) in cases of confirmed chronic traumatic encephalopathy compared to nonathlete controls and cases of Alzheimer disease (09). Noninvasive testing includes use of tau-specific tracers for PET, first developed to aid in diagnosis of Alzheimer disease (10). Although a number of tracers have been developed and validated, the studies have only applied to murine models and postmortem cases of Alzheimer disease (49; 16).

One study did show high signals after injection of the PET ligand 2-(1-{6-[(2-[F-8]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile (FDDNP) in the amygdala and subcortical regions of five symptomatic retired professional American football players compared to healthy controls, although autopsy confirmation of chronic traumatic encephalopathy has yet to be obtained for these patients (44). Additionally, FDDNP is only relatively specific in binding capacity, having an affinity for protein motifs exhibiting a beta-pleated sheet pattern as found in both tau and amyloid neuroaggregates. The quest for a reliable diagnostic evaluation for chronic traumatic encephalopathy involving the use of fluid and imaging biomarkers is an area of burgeoning research, though it is a slow process because autopsy specimen analysis remains the only validated method of definitive diagnosis.

References

01: Alosco ML, Kasimis AB, Stamm JM, et al. Age of first exposure to American football and long-term neuropsychiatric and cognitive outcomes. Transl Psychiatry 2017a;7(9):e1236. PMID 28926003
02: Alosco ML, Mez J, Kowall NW, et al. Cognitive reserve as a modifier of clinical expression in chronic traumatic encephalopathy: a preliminary examination. J Neuropsychiatry Clin Neurosci 2017b;29(1):6-12. PMID 27539377
03: Alosco ML, Tripodis Y, Jarnagin J, et al. Repetitive head impact exposure and later-life plasma total tau in former National Football League players. Alzheimers Dement (Amst) 2016;7:33-40. PMID 28229128
04: Bahrami N, Sharma D, Rosenthal S, et al. Subconcussive head impact exposure and white matter tract changes over a single season of youth football. Radiology 2016;281(3):919-26. PMID 27775478
05: Bieniek KF, Ross OA, Cormier KA, et al. Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. Acta Neuropathol 2015;130(6):877-89. PMID 26518018
06: Broglio SP, Eckner JT, Martini D, Sosnoff JJ, Kutcher JS, Randolph C. Cumulative head impact burden in high school football. J Neurotrauma 2011;28(10):2069-78. PMID 21787201
07: Budson AE, Solomon PR. Memory loss: a practical guide for clinicians. 3rd edition. Edinburgh: Elsevier Saunders, 2021.
08: Cherry J, Meng G, Daley S, et al. CCL2 is associated with microglia and macrophage recruitment in chronic traumatic encephalopathy. J Neuroinflammation 2020;17(1):370. PMID 33278887
09: Cherry JD, Stein TD, Tripodis Y, et al. CCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimer's disease. PLOS ONE 2017;12(9):e0185541. PMID 28950005
10: Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 2013;34(2):457-68. PMID 23234879
11: Corsellis JA, Bruton CJ, Freeman-Browne D. The aftermath of boxing. Psychol Med 1973;3(3):270-303. PMID 4729191
12: Ferrari R, Kapogiannis D, Huey ED, Momeni P. FTD and ALS: a tale of two diseases. Curr Alzheimer Res 2011;8(3):273-94. PMID 21222600
13: Gardner RC, Hess CP, Brus-Ramer M, et al. Cavum septum pellucidum in retired american pro-football players. J Neurotrauma 2016;33(1):157-61. PMID 25970145
14: Grashow R, Weisskopf MG, Baggish A, et al. Premortem chronic traumatic encephalopathy diagnoses in professional football. Ann Neurol 2020;88(1):106-12. PMID 32281676
15: Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol 2010;45(1):30-40. PMID 19853650
16: Harada R, Okamura N, Furumoto S, Tago T, Yanai K, Arai H, et al. Characteristics of Tau and Its Ligands in PET Imaging. Biomolecules 2016;6(1):7. PMID 26751494
17: Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL. Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med 2004;351(1):13-22. PMID 15229303
18: Hoge CW, McGurk D, Thomas JL, Cox AL, Engel CC, Castro CA. Mild traumatic brain injury in U.S. Soldiers returning from Iraq. N Engl J Med 2008;358(5):453-63. PMID 18234750
19: Jordan BD. The clinical spectrum of sport-related traumatic brain injury. Nat Rev Neurol 2013;9(4):222-30. PMID 23478462
20: Kao AW, Racine CA, Quitania LC, Kramer JH, Christine CW, Miller BL. Cognitive and neuropsychiatric profile of the synucleinopathies: Parkinson disease, dementia with Lewy bodies, and multiple system atrophy. Alzheimer Dis Assoc Disord 2009;23(4):365-70. PMID 19935145
21: Katz DI, Bernick C, Dodick DW, et al. National Institute of Neurological Disorders and Stroke consensus diagnostic criteria for traumatic encephalopathy syndrome. Neurology 2021;96(18):848-63. PMID 33722990
22: Langlois JA, Rutland-Brown W, Wald MM. The epidemiology and impact of traumatic brain injury: a brief overview. J Head Trauma Rehabil 2006;21(5):375-8. PMID 16983222
23: Lehman EJ, Hein MJ, Baron SL, Gersic CM. Neurodegenerative causes of death among retired National Football League players. Neurology 2012;79(19):1970-4. PMID 22955124
24: Lesman-Segev OH, La Joie R, Stephens ML, et al. Tau PET and multimodal brain imaging in patients at risk for chronic traumatic encephalopathy. Neuroimage Clin 2019;24:102025. PMID 31670152
25: Mackenzie IR, Rademakers R. The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia. Curr Opin Neurol 2008;21(6): 693-700. PMID 18989115
26: Marquie M, Aguero C, Amaral AC, et al. [18F]-AV-1451 binding profile in chronic traumatic encephalopathy: a postmortem case series. Acta Neuropathol Commun 2019;7(1):164. PMID 31661038
27: Martini D, Eckner J, Kutcher J, Broglio SP. Subconcussive head impact biomechanics: comparing differing offensive schemes. Med Sci Sports Exerc 2013;45(4):755-61. PMID 23135370
28: McKee AC, Robinson ME. Military-related traumatic brain injury and neurodegeneration. Alzheimers Dement 2014;10(3 Suppl):S242-53. PMID 24924675
29: McKee AC, Stein TD, Huber BR, et al. Chronic traumatic encephalopathy (CTE): criteria for neuropathological diagnosis and relationship to repetitive head impacts. Acta Neuropathol 2023;145(4):371-94. PMID 36759368
30: McKee AC, Stern RA, Nowinski CJ, Stein TD, Alvarez VE, Daneshvar DH, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain 2013;136(Pt 1):43-64. PMID 23208308
31: Meehan W 3rd, Mannix R, Zafonte R, Pascual-Leone A. Chronic traumatic encephalopathy and athletes. Neurology 2015;85(17):1504-11. PMID 26253448
32: Mez J, Daneshvar DH, Kiernan PT, Abdolmohammadi B, Alvarez VE, Huber BR, et al. Clinicopathological evaluation of chronic traumatic encephalopathy in players of American football. JAMA 2017;318(4):360-70. PMID 28742910
33: Mez J, Stern RA, McKee AC. Chronic traumatic encephalopathy: where are we and where are we going? Curr Neurol Neurosci Rep 2013;13(12):407. PMID 24136455
34: Montenigro PH, Baugh CM, Daneshvar DH, et al. Clinical subtypes of chronic traumatic encephalopathy: literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome. Alzheimers Res Ther 2014;6(5):68. PMID 25580160
35: Neselius S, Brisby H, Theodorsson A, Blennow K, Zetterberg H, Marcusson J. CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma. PLoS One 2012;7(4):e33606. PMID 22496755
36: Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, et al. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain 2014;137(Pt 6):1762-71. PMID 24681664
37: Okie S. Traumatic brain injury in the war zone. N Engl J Med 2005;352(20):2043-7. PMID 15901856
38: Omalu BI, DeKosky ST, Minster RL, Kamboh MI, Hamilton RL, Wecht CH. Chronic traumatic encephalopathy in a National Football League player. Neurosurgery 2005;57(1):128-34; discussion 128-34. PMID 15987548
39: Omalu BI, Fitzsimmons RP, Hammers J, Bailes J. Chronic traumatic encephalopathy in a professional American wrestler. J Forensic Nurs 2010;6(3):130-6. PMID 21175533
40: Patricios JS, Kemp S. Chronic traumatic encephalopathy: rugby's call for clarity, data and leadership in the concussion debate. Br J Sports Med 2014;48(2):76-9. PMID 24124038
41: Roberts AH. Brain damage in boxers: a study of the prevalence of traumatic encephalopathy among ex-professional boxers. London: Pitman Medical & Scientific Pub Co, 1969.
42: Sephton CF, Cenik B, Cenik BK, Herz J, Yu G. TDP-43 in central nervous system development and function: clues to TDP-43-associated neurodegeneration. Biol Chem 2012;393(7):589-94. PMID 22944662
43: Shively S, Scher AI, Perl DP, Diaz-Arrastia R. Dementia resulting from traumatic brain injury: what is the pathology? Arch Neurol 2012;69(10):1245-51. PMID 22776913
44: Small GW, Kepe V, Siddarth P, et al. PET scanning of brain tau in retired National Football League players: preliminary findings. Am J Geriatr Psychiatry 2013;21(2):138-44. PMID 23343487
45: Stein TD, Montenigro PH, Alvarez VE, et al. Beta-amyloid deposition in chronic traumatic encephalopathy. Acta Neuropathol 2015;130(1):21-34. PMID 25943889
46: Stern RA, Adler CH, Chen K, et al. Tau positron-emission tomography in former National Football League players. N Engl J Med 2019;380(18):1716-25. PMID 30969506
47: Stern RA, Daneshvar DH, Baugh CM, et al. Clinical presentation of chronic traumatic encephalopathy. Neurology 2013;81(13):1122-9. PMID 23966253
48: Turk KW, Geada A, Avarez VE, et al. A comparison between tau and amyloid-β cerebrospinal fluid biomarkers in chronic traumatic encephalopathy and Alzheimer disease. Alzheimers Res Ther 2022;14(1):28. PMID 35139894
49: Xia CF, Arteaga J, Chen G, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement 2013;9(6):666-76. PMID 23411393

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Jason L Weller MD

Dr. Weller of the Boston VA Healthcare System and Boston University School of Medicine has no relevant financial relationships to disclose.
See Profile
Katherine Turk MD

Dr. Turk of the Boston VA Healthcare System and Boston University School of Medicine received research funding from VoxNeuro, Inc. as an investigator.
See Profile
Andrew E Budson MD

Dr. Budson of the Boston VA Healthcare System and Boston University School of Medicine received honorariums from AbbVie and Eli Lilly as a consultant and grant support from Bristol Meyers Squibb and VoxNeuro as principal investigator.
See Profile

Editor

Howard S Kirshner MD

Dr. Kirshner of Vanderbilt University School of Medicine has no relevant financial relationships to disclose.
See Profile

Patient Profile

Age range of presentation: 13 to 65+ years
Sex preponderance: Female = male

(However, studies have a historical male bias due to limited female involvement in contact sports prior to 1972.)
Heredity: Heritability still under investigation
Population groups selectively affected: No current information on specific groups
Occupation groups selectively affected: Contact sports athletes: American football, boxing, ice hockey, soccer, wrestling, mixed martial arts

Military veterans

ICD & OMIM codes

ICD-9: Personality change due to conditions classified elsewhere: 310.1

Postconcussion syndrome: 310.2

Other specified nonpsychotic mental disorders following organic brain damage: 310.8

Unspecified nonpsychotic mental disorder following organic brain damage: 310.9
ICD-10: Organic personality disorder due to brain disease, damage and dysfunction: F07.0

Postencephalitic syndrome: F07.1

Postconcussional syndrome: F07.2

Other organic personality and behavioural disorders due to brain disease, damage and dysfunction: F07.8

Unspecified organic personality and behavioural disorder due to brain disease, damage and dysfunction: F07.9

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Chronic traumatic encephalopathy

Associated Disorders

Alzheimer disease
Amyotrophic lateral sclerosis
Parkinson disease
Lewy body disease

Differential Diagnosis

Alzheimer disease
Fronto-temporal dementia
Lewy body disease
Amyotrophic lateral sclerosis with dementia
Posttraumatic stress disorder
- Chronic postconcussion syndrome

Also Relevant

Amyotrophic lateral sclerosis
Biomarkers in neurology
Chronic subdural hematoma
Frontotemporal dementia
Headache attributed to head trauma
- Memory loss
- Minor closed head injury
- Posttraumatic epilepsy
- Posttraumatic movement disorders
- Posttraumatic sleep disturbance
- Severe closed head injury
- Sexual dysfunction in neurologic disorders
- Sports activities: neurologic complications

Clinical Categories

Neurobehavioral & Cognitive Disorders

Chronic traumatic encephalopathy (CTE) …

Chronic traumatic encephalopathy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Table 1. Most Common Initial Presenting Clinical Features Among Symptomatic Subjects

Table 2. Research Diagnostic Criteria for Traumatic Encephalopathy Syndrome

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Table 3. Preliminary NINDS Pathologic Criteria for Chronic Traumatic Encephalopathy Diagnosis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Outcomes

References

Contributors

Authors

Editor

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Anti-LGI1 encephalitis

Fatal familial insomnia

Hyperventilation syndrome

Neurologic disorders associated with behavioral symptoms

Cortical blindness

Leukodystrophies

Mucopolysaccharidoses

Dementia in Parkinson disease

Chronic traumatic encephalopathy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Table 1. Most Common Initial Presenting Clinical Features Among Symptomatic Subjects

Table 2. Research Diagnostic Criteria for Traumatic Encephalopathy Syndrome

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Table 3. Preliminary NINDS Pathologic Criteria for Chronic Traumatic Encephalopathy Diagnosis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Outcomes

References

Contributors

Authors

Editor

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Anti-LGI1 encephalitis

Fatal familial insomnia

Hyperventilation syndrome

Neurologic disorders associated with behavioral symptoms

Cortical blindness

Leukodystrophies

Mucopolysaccharidoses

Dementia in Parkinson disease

This is an article preview.
Start a Free Account
to access the full version.